Back to Ovarian Cancer
This trial is complete. It is no longer accepting participants. Results may be available on ClinicalTrials.gov.

NCT01719926

NCT01719926
Completed Phase 1

Who may be able to join

Who might be able to join this trial:

  • You have been diagnosed with a cancer that has been confirmed by a tissue sample (biopsy), and you are receiving certain chemotherapy treatments containing cisplatin (with gemcitabine or 5FU/capecitabine) or a combination called CAPOX (oxaliplatin and capecitabine), given in 3-week cycles.
  • You are 18 years of age or older.
  • You have not received platinum-based chemotherapy (a specific type of chemo) for at least 6 months before joining the trial.
  • You have at least one area of cancer that doctors can measure or track.
  • You are in good general health and able to carry out daily activities with little or no limitation (confirm with trial site for exact fitness level required).
  • If you are a woman who could become pregnant, you must be using reliable contraception, have a negative pregnancy test, and agree not to breastfeed during the trial.
  • You are willing and able to give written consent to take part.

Who may not be able to join:

  • You have a known allergy or bad reaction to indomethacin, anti-nausea medications, aspirin, or similar anti-inflammatory medicines.
  • You have cancer that has spread to your brain or the lining around your brain and is causing symptoms.
  • You have epilepsy or seizures that require medication to control.
  • You have uncontrolled high blood pressure, or a history of blood pressure that is hard to manage.
  • You have unstable chest pain (angina), serious heart failure, a recent heart attack (within the last 6 months), or a serious uncontrolled irregular heartbeat.
  • You have an active stomach ulcer, gastritis, or inflammatory bowel disease.
  • You have a history of bleeding in your stomach or digestive system.
  • You have a history of stroke or other problems with blood vessels in the brain.
  • You have a condition that causes problems with blood clotting or unusual bleeding.
  • Your kidneys are not working well enough (confirm with trial site for exact levels required).
  • Your blood counts (white blood cells, platelets, or red blood cells) are too low (confirm with trial site for exact levels required).
  • Certain liver-related blood test results are too high (confirm with trial site for exact levels required).
  • You are unable or unwilling to follow the rules of the trial.
  • You are regularly taking steroid medications (inhaled/nebulised steroids are allowed).
  • You have had radiation therapy within 4 weeks before starting the trial.
  • You have taken part in another experimental treatment within 4 weeks before starting the trial.
  • You have used omega-3 or omega-6 supplements, including fish oil products, within 2 weeks before starting the trial.
  • You regularly use anti-inflammatory painkillers (such as ibuprofen), aspirin, or similar medicines.
  • You are currently taking blood-thinning (anticoagulant) medication.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Trial details

Status
Completed
Phase
Phase 1
Sponsor
UMC Utrecht
Registry
clinicaltrials_gov
Start date
1 September 2012
Est. completion
30 August 2017

Where this trial is recruiting

🇳🇱 Netherlands 🇨🇭 Switzerland

Primary endpoints

Number of dose limiting toxicities at each dosage cohort

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

View original record on ClinicalTrials.gov